⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
YARW News
Yarrow Bioscience, Inc. Common Stock
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
businesswire.com
YARW
Form 8-K
sec.gov
YARW
Form 8-K/A
sec.gov
YARW
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
businesswire.com
YARW
VYNE